Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 24% ± 7% | |
brain | 10 studies | 32% ± 17% | |
peripheral blood | 7 studies | 23% ± 7% | |
liver | 6 studies | 32% ± 14% | |
intestine | 4 studies | 21% ± 4% | |
eye | 4 studies | 29% ± 10% | |
heart | 4 studies | 19% ± 2% | |
kidney | 3 studies | 18% ± 0% | |
adipose | 3 studies | 30% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1999.57 | 1445 / 1445 | 100% | 29.23 | 183 / 183 |
lung | 100% | 3116.02 | 578 / 578 | 100% | 27.03 | 1155 / 1155 |
ovary | 100% | 1912.94 | 180 / 180 | 100% | 29.90 | 430 / 430 |
breast | 100% | 3539.21 | 459 / 459 | 100% | 28.97 | 1116 / 1118 |
stomach | 100% | 1512.34 | 359 / 359 | 100% | 21.90 | 285 / 286 |
bladder | 100% | 2653.14 | 21 / 21 | 100% | 20.02 | 502 / 504 |
thymus | 100% | 2320.31 | 653 / 653 | 99% | 34.19 | 601 / 605 |
intestine | 100% | 2219.92 | 966 / 966 | 99% | 20.36 | 523 / 527 |
brain | 99% | 1284.50 | 2625 / 2642 | 100% | 23.41 | 704 / 705 |
uterus | 100% | 2030.29 | 170 / 170 | 99% | 21.83 | 454 / 459 |
prostate | 100% | 1814.80 | 245 / 245 | 99% | 15.10 | 496 / 502 |
adrenal gland | 100% | 2246.53 | 258 / 258 | 98% | 15.87 | 226 / 230 |
kidney | 100% | 1454.99 | 89 / 89 | 98% | 20.20 | 883 / 901 |
liver | 100% | 1600.77 | 226 / 226 | 97% | 14.95 | 393 / 406 |
pancreas | 96% | 885.41 | 316 / 328 | 98% | 24.60 | 175 / 178 |
skin | 100% | 2853.91 | 1809 / 1809 | 92% | 17.88 | 432 / 472 |
adipose | 100% | 3129.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 35.00 | 29 / 29 |
muscle | 100% | 2579.57 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2760.37 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.25 | 1 / 1 |
blood vessel | 100% | 2488.42 | 1334 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 21.28 | 44 / 45 |
peripheral blood | 96% | 2543.13 | 889 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 1170.30 | 819 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 56% | 5.09 | 45 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000158 | Biological process | positive regulation of ubiquitin-specific protease activity |
GO_0007165 | Biological process | signal transduction |
GO_0051607 | Biological process | defense response to virus |
GO_0006974 | Biological process | DNA damage response |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
GO_1903003 | Biological process | positive regulation of protein deubiquitination |
GO_0071479 | Biological process | cellular response to ionizing radiation |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0032991 | Cellular component | protein-containing complex |
GO_1902554 | Cellular component | serine/threonine protein kinase complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0035800 | Molecular function | deubiquitinase activator activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0140678 | Molecular function | molecular function inhibitor activity |
Gene name | TANK |
Protein name | TRAF family member-associated NF-kappa-B activator (TRAF-interacting protein) (I-TRAF) Uncharacterized protein TANK TRAF family member associated NFKB activator TANK protein |
Synonyms | TRAF2 ITRAF |
Description | FUNCTION: Adapter protein involved in I-kappa-B-kinase (IKK) regulation which constitutively binds TBK1 and IKBKE playing a role in antiviral innate immunity. Acts as a regulator of TRAF function by maintaining them in a latent state. Blocks TRAF2 binding to LMP1 and inhibits LMP1-mediated NF-kappa-B activation. Negatively regulates NF-kappaB signaling and cell survival upon DNA damage . Plays a role as an adapter to assemble ZC3H12A, USP10 in a deubiquitination complex which plays a negative feedback response to attenuate NF-kappaB activation through the deubiquitination of IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage . Promotes UBP10-induced deubiquitination of TRAF6 in response to DNA damage . May control negatively TRAF2-mediated NF-kappa-B activation signaled by CD40, TNFR1 and TNFR2. . |
Accessions | ENST00000392749.7 [Q92844-1] E7EWR8 ENST00000432692.6 ENST00000432002.5 ENST00000441987.5 Q4ZG76 E7ENY2 ENST00000402568.5 ENST00000406287.5 Q53TI5 H7C3L4 ENST00000405852.5 E7EVA2 H7BZ28 E7EQA9 ENST00000456358.5 E7EW82 E7EMT6 E7EM55 ENST00000457887.5 ENST00000437623.1 ENST00000440506.5 Q6NW12 ENST00000439442.1 ENST00000259075.6 [Q92844-1] ENST00000403609.1 [Q92844-3] E9PEK1 Q92844 ENST00000429217.5 E7EV32 E7ERM9 |